Stoke Therapeutics (STOK) Cash from Investing Activities Growth (3y) (2021 - 2026)
Powered by 
Analysis
Stoke Therapeutics (STOK) Cash from Investing Activities Growth (3y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.26 Bn | 131.41 Bn | 2.84 Bn | 46.78% |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | 66.14% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.83 Bn | 52.69 Bn | 52.00 Mn | -44.69% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.94 Bn | 34.84 Bn | 1.53 Bn | -39.73% |
| 7 | Alnylam Pharmaceuticals | 35.19 Bn | 31.88 Bn | 992.69 Mn | -246.81% |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | -53.57% |
| 9 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 27.84% |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | -27.30% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -27.30% |
| Mar 31, 2026 | -1.52% |
| Dec 31, 2025 | -67.69% |
| Sep 30, 2025 | -48.68% |
| Jun 30, 2025 | -906.28% |
| Mar 31, 2025 | 28.07% |
| Dec 31, 2024 | -58.90% |
| Sep 30, 2024 | -78.63% |
| Jun 30, 2024 | -2.18% |
| Mar 31, 2024 | 270.75% |
| Dec 31, 2023 | 449.72% |
| Sep 30, 2023 | 283.36% |
| Jun 30, 2023 | 563.27% |
| Mar 31, 2023 | 346.52% |
| Dec 31, 2022 | 246.29% |
| Sep 30, 2022 | 389.62% |
| Jun 30, 2022 | 33.37% |
| Mar 31, 2022 | -1,046.92% |
| Dec 31, 2021 | 424.31% |
| Sep 30, 2021 | -116.88% |